Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focussed on developing coronavirus solutions….
Canadian Biotech
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin….
For the last eight months, the Covid-19 virus has been the center of attention in the media, the markets, and the medical field. Collectively, countries and government agencies, and…
Revive Therapeutics is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (Covid-19)…
“More than 4 million adults experience chronic daily migraine – with at least 15 migraine days per month,” states The Migraine Research Foundation, “It affects 39 million people in the U.S….
A Harvard University Study calculates the economic burden from diabetes at about $1.3 trillion, or 1.8% of global GDP….